1. Key Insights 2. Neuroblastoma Market Overview At A Glance 3. Market Share (%) Distribution Of Neuroblastoma In 2016 4. Market Share (%) Distribution Of Neuroblastoma In 2028 5. Disease Background And Overview 6. INTRODUCTION 6.1. STAGES OF NEUROBLASTOMA 6.1.1. International Neuroblastoma Staging System (INSS) 6.1.2. International Neuroblastoma Risk Group Staging System (INRGSS) 6.2. NEUROBLASTOMA RISK GROUPS 6.2.1. Children’s Oncology Group (COG) Risk Group Classification 6.2.2. International Neuroblastoma Risk Group (INRG) classification 6.2.3. COG and INRG Classifications 6.2.4. Current COG Neuroblastoma Risk Stratification 6.3. SIGNS AND SYMPTOMS 6.4. ETIOLOGY 6.5. PATHOGENESIS 6.6. THERAPEUTIC TARGETS FOR NEUROBLASTOMA 6.7. DIAGNOSIS 7. Epidemiology And Patient Population 8. Key Findings 9. Population And Forecast Parameters 10. 7MM Total Incident Patient Population Of Neuroblastoma 11. Country Wise-Epidemiology Of Neuroblastoma 11.1. United States 11.1.1. Total Incident Patient Population of Neuroblastoma in the United States 11.1.2. Distribution of Incident cases by Risk Groups – Neuroblastoma 11.2. EU5 Countries 11.3. Germany 11.3.1. Total Incident Patient Population of Neuroblastoma in Germany 11.3.2. Distribution of Incident cases by Risk Groups – Neuroblastoma 11.4. France 11.4.1. Total Incident Patient Population of Neuroblastoma in France 11.4.2. Distribution of Incident cases by Risk Groups – Neuroblastoma 11.5. United Kingdom 11.5.1. Total Incident Patient Population of Neuroblastoma in the United Kingdom 11.5.2. Distribution of Incident cases by Risk Groups – Neuroblastoma 11.6. Spain 11.6.1. Total Incident Patient Population of Neuroblastoma in Spain 11.6.2. Distribution of Incident cases by Risk Groups – Neuroblastoma 11.7. Italy 11.7.1. Total Incident Patient Population of Neuroblastoma in Italy 11.7.2. Distribution of Incident cases by Risk Groups – Neuroblastoma 11.8. Japan 11.8.1. Total Incident Patient Population of Neuroblastoma in Japan 11.8.2. Distribution of Incident cases by Risk Groups – Neuroblastoma 12. CURRENT TREATMENT AND MEDICAL PRACTICES 12.1. American Cancer Society Recommendations 12.2. American Society Of Clinical Oncology Recommendations 12.3. Cancer Research United Kingdom Treatment Recommendations 12.4. Gesellschaft Für Pädiatrische Onkologie Und Hämatologie (Gpoh) Recommendations 12.5. Siop-podc Adapted Risk Stratification And Treatment Guidelines Recommendations For Neuroblastoma 12.6. Top 6 Associations For Neuroblastoma 13. MARKETED DRUGS 13.1. UNITUXIN: UNITED THERAPEUTICS CORP 13.1.1. Drug Description 13.1.2. Mechanism of Action 13.1.3. Regulatory Milestones 13.1.4. Safety and Efficacy 13.1.5. Product Profile 13.1.6. Side-Effects 13.2. QARZIBA: EUSA PHARMA 13.2.1. Drug Description 13.2.2. Mechanism of Action 13.2.3. Regulatory Milestones 13.2.4. Safety and Efficacy 13.2.5. Product Profile 13.2.6. Side-Effects 14. KEY-CROSS COMPETITION 15. PIPELINE PROFILES 15.1. NAXITAMAB: Y-MABS THERAPEUTICS INC 15.1.1. Regulatory Milestones 15.1.2. Other Development Activities 15.1.3. Clinical Development 15.1.4. Clinical Trials Information 15.1.5. Product Profile 15.2. OMBURTAMAB: Y-MABS THERAPEUTICS INC 15.2.1. Regulatory Milestones 15.2.2. Other development activities 15.2.3. Clinical Development 15.2.4. Clinical Trials Information 15.2.5. Safety and Efficacy 15.2.6. Product Profile 15.3. BEVACIZUMAB + IRINOTECAN +TEMOZOLOMIDE: GENENTECH, INC 15.3.1. Clinical Development 15.3.2. Clinical Trials Information 15.3.3. Safety and Efficacy 15.3.4. Product Profile 15.4. MNX-100: METRONOMX 15.4.1. Other Development Activities 15.4.2. Clinical Development 15.4.3. Clinical Trials Information 15.4.4. Safety and Efficacy 15.4.5. Product Profile 15.5. CPP-1X: CANCER PREVENTION PHARMACEUTICALS 15.5.1. Regulatory Milestones 15.5.2. Other Development Activities 15.5.3. Clinical Development 15.5.4. Clinical Trials Information 15.5.5. Product Profile 16. NEUROBLASTOMA: MARKET ANALYSIS 16.1. Key Findings 16.2. Market Outlook: 7 Major Markets 16.3. Market Size Of Neuroblastoma In 7mm (2016-2028) 16.4. Risk Group Wise Market Size Of Neuroblastoma in 7MM (2016-2028) 16.5. Therapy Wise Market Size Of Neuroblastoma In 7MM (2016-2028) 16.6. NEUROBLASTOMA: US MARKET OUTLOOK 16.6.1. US Market Size 16.6.2. Risk Group wise Market Size 16.6.3. Therapy wise Market size 16.7. NEUROBLASTOMA: EU5 MARKET OUTLOOK 16.8. GERMANY MARKET SIZE 16.8.1. Risk Group wise Market Size 16.8.2. Therapy wise Market size 16.9. FRANCE MARKET SIZE 16.9.1. Risk Group wise Market Size 16.9.2. Therapy wise Market size 16.10. UNITED KINGDOM MARKET SIZE 16.10.1. Risk Group wise Market Size 16.10.2. Therapy wise Market size 16.11. SPAIN MARKET SIZE 16.11.1. Risk Group wise Market Size 16.11.2. Therapy wise Market size 16.12. ITALY MARKET SIZE 16.12.1. Risk Group wise Market Size 16.12.2. Therapy wise Market size 16.13. NEUROBLASTOMA: JAPAN MARKET OUTLOOK 16.13.1. JAPAN MARKET SIZE 16.13.2. Risk Group wise Market Size 16.13.3. Therapy wise Market size 17. MARKET DRIVERS 18. MARKET BARRIERS 19. APPENDIX 20. REPORT METHODOLOGY 20.1. Sources used 21. DELVEINSIGHT CAPABILITIES 22. DISCLAIMER 23. ABOUT DELVEINSIGHT

TABLE 1: TOTAL INCIDENT PATIENT POPULATION OF NEUROBLASTOMA IN THE 7MM (2016-2028) TABLE 2: TOTAL INCIDENT PATIENT POPULATION OF NEUROBLASTOMA IN THE UNITED STATES (2016-2028) TABLE 3: INCIDENT PATIENT POPULATION OF NEUROBLASTOMA BY RISK GROUPS IN THE UNITED STATES (2016-2028) TABLE 4: TOTAL INCIDENT PATIENT POPULATION OF NEUROBLASTOMA IN GERMANY (2016-2028) TABLE 5: INCIDENT PATIENT POPULATION OF NEUROBLASTOMA BY RISK GROUPS IN GERMANY (2016-2028) TABLE 6: TOTAL INCIDENT PATIENT POPULATION OF NEUROBLASTOMA IN FRANCE (2016-2028) TABLE 7: INCIDENT PATIENT POPULATION OF NEUROBLASTOMA BY RISK GROUPS IN FRANCE (2016-2028) TABLE 8: TOTAL INCIDENT PATIENT POPULATION OF NEUROBLASTOMA IN THE UNITED KINGDOM (2016-2028) TABLE 9: INCIDENT PATIENT POPULATION OF NEUROBLASTOMA BY RISK GROUPS IN THE UNITED KINGDOM (2016-2028) TABLE 10: TOTAL INCIDENT PATIENT POPULATION OF NEUROBLASTOMA IN SPAIN (2016-2028) TABLE 11: INCIDENT PATIENT POPULATION OF NEUROBLASTOMA BY RISK GROUPS IN SPAIN (2016-2028) TABLE 12: TOTAL INCIDENT PATIENT POPULATION OF NEUROBLASTOMA IN ITALY (2016-2028) TABLE 13: INCIDENT PATIENT POPULATION OF NEUROBLASTOMA BY RISK GROUPS IN ITALY (2016-2028) TABLE 14: TOTAL INCIDENT PATIENT POPULATION OF NEUROBLASTOMA IN JAPAN (2016-2028) TABLE 15: INCIDENT PATIENT POPULATION OF NEUROBLASTOMA BY RISK GROUPS IN JAPAN (2016-2028) TABLE 16: KEY-CROSS COMPARISION OF POTENTIAL THERAPIES TABLE 17: POTENTIAL THERAPIES : SAFETY AND EFFICACY TABLE 18: NAXITAMAB CLINICAL TRIAL DESCRIPTION, 2016 TABLE 19: OMBURTAMAB, CLINICAL TRIAL DESCRIPTION, 2016 TABLE 20: OMBURTAMAB : SAFETY AND EFFICACY TABLE 21: (BEVACIZUMAB+ IRINOTECAN +TEMOZOLOMIDE), CLINICAL TRIAL DESCRIPTION, 2016 TABLE 22: (BEVACIZUMAB+ IRINOTECAN +TEMOZOLOMIDE) : SAFETY AND EFFICACY TABLE 23: MNX-100,CLINICAL TRIAL DESCRIPTION, 2016 TABLE 24: MNX-100: SAFETY AND EFFICACY TABLE 25: CPP-1X ,CLINICAL TRIAL DESCRIPTION, 2016 TABLE 26: 7 MAJOR MARKET SIZE OF NEUROBLASTOMA IN USD MILLION (2016-2028) TABLE 27: RISK GROUP WISE MARKET SIZE OF NEUROBLASTOMA IN THE 7MM (2016-2028) TABLE 28: THERAPY WISE MARKET SIZE OF NEUROBLASTOMA IN THE 7MM (2016-2028) TABLE 29: MARKET SIZE OF NEUROBLASTOMA IN THE UNITED STATES, USD MILLIONS (2016-2028) TABLE 30: RISK GROUP WISE MARKET SIZE OF NEUROBLASTOMA IN THE UNITED STATES, USD MILLIONS (2016-2028) TABLE 31: THERAPY-WISE MARKET SIZE OF NEUROBLASTOMA IN UNITED STATES, USD MILLIONS (2016-2028) TABLE 32: MARKET SIZE OF NEUROBLASTOMA IN GERMANY, USD MILLIONS (2016-2028) TABLE 33: RISK GROUP WISE MARKET SIZE OF NEUROBLASTOMA IN GERMANY, USD MILLIONS (2016-2028) TABLE 34: THERAPY-WISE MARKET SIZE OF NEUROBLASTOMA IN GERMANY, USD MILLIONS (2016-2028) TABLE 35: MARKET SIZE OF NEUROBLASTOMA IN FRANCE, USD MILLIONS (2016-2028) TABLE 36: RISK GROUP WISE MARKET SIZE OF NEUROBLASTOMA IN FRANCE, USD MILLIONS (2016-2028) TABLE 37: THERAPY-WISE MARKET SIZE OF NEUROBLASTOMA IN FRANCE, USD MILLIONS (2016-2028) TABLE 38: MARKET SIZE OF NEUROBLASTOMA IN THE UNITED KINGDOM, USD MILLIONS (2016-2028) TABLE 39: RISK GROUP WISE MARKET SIZE OF NEUROBLASTOMA IN THE UNITED KINGDOM, USD MILLIONS (2016-2028) TABLE 40: THERAPY-WISE MARKET SIZE OF NEUROBLASTOMA IN THE UNITED KINGDOM, USD MILLIONS (2016-2028) TABLE 41: MARKET SIZE OF NEUROBLASTOMA IN SPAIN, USD MILLIONS (2016-2028) TABLE 42: RISK GROUP WISE MARKET SIZE OF NEUROBLASTOMA IN SPAIN, USD MILLIONS (2016-2028) TABLE 43: THERAPY-WISE MARKET SIZE OF NEUROBLASTOMA IN SPAIN, USD MILLIONS (2016-2028) TABLE 44: MARKET SIZE OF NEUROBLASTOMA IN ITALY, USD MILLIONS (2016-2028) TABLE 45: RISK GROUP WISE MARKET SIZE OF NEUROBLASTOMA IN ITALY, USD MILLIONS (2016-2028) TABLE 46: THERAPY-WISE MARKET SIZE OF NEUROBLASTOMA IN ITALY, USD MILLIONS (2016-2028) TABLE 47: MARKET SIZE OF NEUROBLASTOMA IN JAPAN, USD MILLIONS (2016-2028) TABLE 48: RISK GROUP WISE MARKET SIZE OF NEUROBLASTOMA IN JAPAN, USD MILLIONS (2016-2028) TABLE 49: THERAPY-WISE MARKET SIZE OF NEUROBLASTOMA IN JAPAN, USD MILLIONS (2016-2028) FIGURE 1: STAGING OF NEUROBLASTOMA FIGURE 2: SIGNS AND SYMPTOMS OF NEUROBLASTOMA FIGURE 3: PATHOGENESIS OF NEUROBLASTOMA FIGURE 4: THERAPEUTIC TARGETS FOR NEUROBLASTOMA FIGURE 5: INITIAL DIAGNOSTIC WORK FOR NEUROBLASTOMA FIGURE 6: TOTAL INCIDENT PATIENT POPULATION OF NEUROBLASTOMA IN THE 7MM (2016-2028) FIGURE 7: TOTAL INCIDENT PATIENT POPULATION OF NEUROBLASTOMA IN THE UNITED STATES (2016-2028) FIGURE 8: INCIDENT PATIENT POPULATION OF NEUROBLASTOMA BY RISK GROUPS IN THE UNITED STATES (2016-2028) FIGURE 9: TOTAL INCIDENT PATIENT POPULATION OF NEUROBLASTOMA IN GERMANY (2016-2028) FIGURE 10: INCIDENT PATIENT POPULATION OF NEUROBLASTOMA BY RISK GROUPS IN GERMANY (2016-2028) FIGURE 11: TOTAL INCIDENT PATIENT POPULATION OF NEUROBLASTOMA IN FRANCE (2016-2028) FIGURE 12: INCIDENT PATIENT POPULATION OF NEUROBLASTOMA BY RISK GROUPS IN FRANCE (2016-2028) FIGURE 13: TOTAL INCIDENT PATIENT POPULATION OF NEUROBLASTOMA IN THE UNITED KINGDOM (2016-2028) FIGURE 14: INCIDENT PATIENT POPULATION OF NEUROBLASTOMA BY RISK GROUPS IN THE UNITED KINGDOM (2016-2028) FIGURE 15: TOTAL INCIDENT PATIENT POPULATION OF NEUROBLASTOMA IN SPAIN (2016-2028) FIGURE 16: INCIDENT PATIENT POPULATION OF NEUROBLASTOMA BY RISK GROUPS IN SPAIN (2016-2028) FIGURE 17: TOTAL INCIDENT PATIENT POPULATION OF NEUROBLASTOMA IN ITALY (2016-2028) FIGURE 18: INCIDENT PATIENT POPULATION OF NEUROBLASTOMA BY RISK GROUPS IN ITALY (2016-2028) FIGURE 19: TOTAL INCIDENT PATIENT POPULATION OF NEUROBLASTOMA IN JAPAN (2016-2028) FIGURE 20: INCIDENT PATIENT POPULATION OF NEUROBLASTOMA BY RISK GROUPS IN JAPAN (2016-2028) FIGURE 21: GENERAL TREATMENT OF NEUROBLASTOMA FIGURE 22: TREATMENT ALGORITHM OF NEUROBLASTOMA FIGURE 23: RISK STRATIFICATION OF NEUROBLASTOMA FIGURE 24: TREATMENT ALGORITHM OF NEUROBLASTOMA FIGURE 25: TOTAL MARKET SIZE OF NEUROBLASTOMA IN THE 7MM (2016-2028) FIGURE 26: RISK GROUP WISE MARKET SIZE OF NEUROBLASTOMA IN THE 7MM (2016-2028) FIGURE 27: THERAPY WISE MARKET SIZE OF NEUROBLASTOMA IN THE 7MM (2016-2028) FIGURE 28: MARKET SIZE OF NEUROBLASTOMA IN THE UNITED STATES, USD MILLIONS (2016-2028) FIGURE 29: RISK GROUP WISE MARKET SIZE OF NEUROBLASTOMA IN THE UNITED STATES, USD MILLIONS (2016-2028) FIGURE 30: THERAPY-WISE MARKET SIZE OF NEUROBLASTOMA IN UNITED STATES, USD MILLIONS (2016-2028) FIGURE 31: MARKET SIZE OF NEUROBLASTOMA IN GERMANY, USD MILLIONS (2016-2028) FIGURE 32: RISK GROUP WISE MARKET SIZE OF NEUROBLASTOMA IN GERMANY, USD MILLIONS (2016-2028) FIGURE 33: THERAPY-WISE MARKET SIZE OF NEUROBLASTOMA IN GERMANY, USD MILLIONS (2016-2028) FIGURE 34: MARKET SIZE OF NEUROBLASTOMA IN FRANCE, USD MILLIONS (2016-2028) FIGURE 35: RISK GROUP WISE MARKET SIZE OF NEUROBLASTOMA IN FRANCE, USD MILLIONS (2016-2028) FIGURE 36: THERAPY-WISE MARKET SIZE OF NEUROBLASTOMA IN FRANCE, USD MILLIONS (2016-2028) FIGURE 37: MARKET SIZE OF NEUROBLASTOMA IN THE UNITED KINGDOM, USD MILLIONS (2016-2028) FIGURE 38: RISK GROUP WISE MARKET SIZE OF NEUROBLASTOMA IN THE UNITED KINGDOM, USD MILLIONS (2016-2028) FIGURE 39: THERAPY-WISE MARKET SIZE OF NEUROBLASTOMA IN THE UNITED KINGDOM, USD MILLIONS (2016-2028) FIGURE 40: MARKET SIZE OF NEUROBLASTOMA IN SPAIN, USD MILLIONS (2016-2028) FIGURE 41: RISK GROUP WISE MARKET SIZE OF NEUROBLASTOMA IN SPAIN, USD MILLIONS (2016-2028) FIGURE 42: THERAPY-WISE MARKET SIZE OF NEUROBLASTOMA IN SPAIN, USD MILLIONS (2016-2028) FIGURE 43: MARKET SIZE OF NEUROBLASTOMA IN ITALY, USD MILLIONS (2016-2028) FIGURE 44: RISK GROUP WISE MARKET SIZE OF NEUROBLASTOMA IN ITALY, USD MILLIONS (2016-2028) FIGURE 45: THERAPY-WISE MARKET SIZE OF NEUROBLASTOMA IN ITALY, USD MILLIONS (2016-2028) FIGURE 46: MARKET SIZE OF NEUROBLASTOMA IN JAPAN, USD MILLIONS (2016-2028) FIGURE 47: RISK GROUP WISE MARKET SIZE OF NEUROBLASTOMA IN JAPAN, USD MILLIONS (2016-2028) FIGURE 48: THERAPY-WISE MARKET SIZE OF NEUROBLASTOMA IN JAPAN, USD MILLIONS (2016-2028) FIGURE 49: MARKET DRIVERS FIGURE 50: MARKET BARRIERS